Movers and SHAKERS
Thursday, May 14, 2020
PDS Biotechnology Corp (PDSB)
Q1 Highlighted by Foray into Infectious Diseases Area
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is primarily engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
Cosme Ordonez, Senior Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Q1/F2020 Financial Results in line with our expectations.PDS Biotechnology yesterday announced financial results for Q1/F2020. The Company reported a net loss of $4.0 mm, or $0.39 per basic share and fully diluted share. In our view, the highlight of the quarter was the expansion of the Company's product pipeline into infectious diseases. Now, PDS has Versamune vaccine programs in cancer, tuberculosis, influenza and COVID-19.
Versamune is a versatile vaccine platform technology.The Company is developing a platform technology known as Versamune, which consists of lipid nanoparticles designed to deliver disease-specific antigens to stimulate a potent immune response consisting of both humoral (antibodies) and cellular immunity. Versamune has potential applications for the treatment of cancer and...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.